These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27133391)

  • 21. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.
    Bratu S; Tolaney P; Karumudi U; Quale J; Mooty M; Nichani S; Landman D
    J Antimicrob Chemother; 2005 Jul; 56(1):128-32. PubMed ID: 15917285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin.
    Kontopoulou K; Protonotariou E; Vasilakos K; Kriti M; Koteli A; Antoniadou E; Sofianou D
    J Hosp Infect; 2010 Sep; 76(1):70-3. PubMed ID: 20705205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
    Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom.
    Woodford N; Zhang J; Warner M; Kaufmann ME; Matos J; Macdonald A; Brudney D; Sompolinsky D; Navon-Venezia S; Livermore DM
    J Antimicrob Chemother; 2008 Dec; 62(6):1261-4. PubMed ID: 18812425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
    Clancy CJ; Hao B; Shields RK; Chen L; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3521-5. PubMed ID: 24566172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?
    Antochevis LC; Magagnin CM; Nunes AG; Goulart TM; Martins AS; Cayô R; Gales AC; Barth AL; Zavascki AP
    J Glob Antimicrob Resist; 2018 Dec; 15():173-177. PubMed ID: 30071353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
    Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae.
    Yu W; Shen P; Bao Z; Zhou K; Zheng B; Ji J; Guo L; Huang C; Xiao Y
    Int J Antimicrob Agents; 2017 Aug; 50(2):237-241. PubMed ID: 28648647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant Klebsiella pneumoniae strains.
    Morici P; Florio W; Rizzato C; Ghelardi E; Tavanti A; Rossolini GM; Lupetti A
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1739-1748. PubMed ID: 28470337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of doxycycline in the therapy of multidrug-resistant E. coli - an in vitro study.
    Lai CC; Chen CC; Huang HL; Chuang YC; Tang HJ
    Sci Rep; 2016 Aug; 6():31964. PubMed ID: 27534373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing
    Huang Y; Sokolowski K; Rana A; Singh N; Wang J; Chen K; Lang Y; Zhou J; Kadiyala N; Krapp F; Ozer EA; Hauser AR; Li J; Bulitta JB; Bulman ZP
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0069221. PubMed ID: 34152820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.
    Gatti M; Raschi E; De Ponti F
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):65. PubMed ID: 31718688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Cebrero-Cangueiro T; Álvarez-Marín R; Labrador-Herrera G; Smani Y; Cordero-Matía E; Pachón J; Pachón-Ibáñez ME
    Front Cell Infect Microbiol; 2018; 8():363. PubMed ID: 30406040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Porins and bla
    Balabanian G; Rose M; Manning N; Landman D; Quale J
    Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates.
    Stein C; Makarewicz O; Bohnert JA; Pfeifer Y; Kesselmeier M; Hagel S; Pletz MW
    PLoS One; 2015; 10(6):e0126479. PubMed ID: 26067824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.